POLYCYSTIC OVARY SYNDROME (PCOS) is one of the most common endocrinological problems in women. In addition to chronic oligo-anovulation, the main features of the PCOS include elevated levels of circulating androgens and/or clinical hyperandrogenism, polycystic ovary morphology, altered gonadotropin secretion, insulin resistance and/or compensatory hyperinsulinemia often associated with obesity [1] . Women affected by PCOS also show a higher risk of type 2 diabetes, dyslipidemia, hypertension and cardiovascular diseases [2] [3] [4] .
traceptives, glucocorticoids, ovulation induction agents, anti-obesity drugs, and estrogenic, anti-androgenic or anti-hypertensive medication. The same exclusion criteria applied to controls. Subjects of this study were also studied in another research regarding association of plasma omentin 1 level with PCOS by Choi et al. [18] . The Ethical Committee of Kangbuk Samsung Hospital, Sungkyunkwan University, approved the experimental protocols and all participants provided written informed consents prior to participation in the study.
We subdivided both PCOS and control groups into two subgroups according to the International Obesity Task Force (IOTF) and body mass index (BMI) cutpoints for obesity proposed by the World Health Organization in adult Asian [19] . Women with PCOS were subdivided into the non-obese group (BMI <23.0 Kg/m 2 , n=67) and the overweight/obese group (BMI ≥23.0 Kg/m 2 , n=20). In the control group, there were 49 women subdivided into the non-obese group and four women were placed in the overweight/obese group.
Clinical and biochemical measurements
Clinical variables such as weight, height and blood pressure were assessed in all subjects using standard protocols during a visit to the outpatient department; BMI was calculated as weight divided by height squared (Kg/m 2 ). Serum glucose, C-peptide and insulin levels were measured during fasting and 2 hrs post oral glucose load. Fasting blood samples were obtained for analysis of hormones, lipids, and adiponectin. The hexokinase method was used to measure glucose levels and an enzymatic calorimetric test was used to measure the total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Insulin was measured by an immunoradiometric assay (DiaSource, Nivelles, Belgium). C-peptide was measured by radioimmunoassay method using a commercial kit (BioSource, Europe S.A.). The homeostasis model assessment of insulin resistance (HOMA-IR) was derived from calculations according to the following formula: fasting insulin (mU/mL) × fasting glucose (mmol/L)/22.5 [20] . High-sensitivity C-reactive protein (hs-CRP) levels were measured by immunonephelometry (Dade Behering Co., Marburg, Germany). Women with PCOS and control subjects were evaluated for serum luteinizing hormone (LH), total testosterone, free testosterone, estradiol (E2), 17α-OH-progesterone (17-OH-P), dehydroepiandrostenedione sulfate (DHEA-S) and sex hor- [11, 12] . Androgen production, hyperinsulinemia, and an intrinsic over-expression of the AMH gene are candidates for causing the increased production of AMH in PCOS [13, 14] .
The aim of the present study was to compare the associations of AMH with clinical or biochemical characteristics between women with and without PCOS. In addition, we explored the optimal cutoff point of AMH to diagnose PCOS.
Patients and Methods

Subjects and study design
A total of 140 pre-menopausal Korean women with PCOS (n=87) and without PCOS (n=53) were recruited from the Gynecology clinic of the Kangbuk Samsung Hospital, Seoul, South Korea. Control subjects were healthy volunteers recruited through advertisements at the hospital. PCOS was defined when at least two of the following three symptoms were exhibited, according to the Rotterdam criteria [15] : 1) irregular mense (IM) (≤ 6/yr) due to oligo-or anovulation, 2) clinical (hirsuitism/ acne) and/or biochemical hyperandrogenism (HA), and 3) typical ovarian features (≥ 12 follicles with size of 2-9 mm/ovary) present during transvaginal ultrasound examination. Clinical HA was defined by a modified Ferriman and Gallwey score of more than 8 [16] , and biochemical HA was defined as an elevation of serum testosterone levels above 97.5 percentile limits, which is >0.6 ng/ mL (2.1 nmol/L) for total testosterone and 2.07 ng/mL (7.2 nmol/L) for free testosterone level. When the subjects with PCOS were divided into four subgroups, the proportions in the individual groups are as follows [17] : 1) the IM/HA/PCO group (n=43, 491%), 2) the IM/PCO group (n=34, 39.6%), 3) the IM/HA group (n=9, 9.8%), and 4) the HA/PCS group (n=1, 1.5%). Control subjects were women with regular menstrual cycles (25-35 days) and had no evidence of hirsutism, acne, alopecia or endocrine dysfunction, and no polycystic ovary (< 12 follicles with size of 2-9 mm/ovary). Exclusion criteria for this study included age above 40 years, known cardiovascular disease, thyroid disease, neoplasms, currently smoking, hypertension (blood pressure above 140/90 mmHg), renal impairment (serum creatinine >1.2 mg/dL), and other endocrinopathies causing the same phenotype such as congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome. None of the subjects had taken any medications for at least six months prior to the study, including oral con-trols is summarized in Table 1 . AMH levels remained significantly (p <0.001) higher in PCOS women (mean 11.58 ng/mL; range, 0.34-46.44 ng/mL) than in controls (mean 5.38 ng/mL; range, 0.30-16.09 ng/mL), after adjusting for age and BMI.
We also compared all variables after classification of PCOS women and controls according to BMI, i.e. overweight/obese PCOS women, non-obese PCOS women, overweight/obese controls and non-obese controls ( Table 2 ). Overweight/obese women with PCOS had significantly higher BMI, 2-h post glucose, C-peptide and insulin at both fasting and 2 hrs after glucose loading, HOMA-IR, FAI and lower SHBG levels compared with the other three groups. Overweight/obese PCOS women also showed higher fasting glucose, hs-CRP, total testosterone and free testosterone levels than all controls. In all of the women with PCOS, irrespective of obesity, significantly higher AMH levels were observed compared with control subjects, however, no significant differences in the AMH levels were observed between the two subgroups of women with PCOS.
Correlations of AMH level with clinical and biochemical variables
In the control group, AMH levels showed positive correlations with total testosterone (p <0.001), free testosterone (p=0.024), FAI (p=0.002) and adiponectin (p=0.002), and showed negative correlation with age (p=0.010) and E2 (p=0.012) ( Table 3) . However, only total and free testosterone levels showed significant positive correlations with serum AMH level (p=0.012 and p=0.044, respectively) in PCOS group.
Regression analysis for independent determinants of serum AMH level
To establish independent determinants of serum AMH levels, regression analysis using GLM was performed in PCOS and control groups, and differences in the relationships between the two groups were also evaluated ( Table 4) . We determined variables entered into the regression analysis as variables showing significant differences between PCOS and control groups or significant correlations with AMH level.
Among HOMA-IR, LH, E2, total testosterone, DHEA-S, PRL and adiponectin levels, only total testosterone contributed significantly to serum AMH levels in PCOS group, while total testosterone, E2 and adiponectin levels contributed significantly to serum AMH levels in control group. mone-binding globulin (SHBG) using radioimmunoassay method (Simens, Los Angeles, CA, USA). Serum levels of follicle stimulating hormone (FSH) and prolactin (PRL) were also measured using radioimmunoassay method (DiaSource, Nivelles, Belgium). The free androgen index (FAI) was expressed according to the formula (TT/SHBG)×100. Serum levels of AMH were measured with a second generation enzyme immunoassay AMH-EIA (reference A16507; ImmunotechCoulter, Marseille, France) as previously described [21] . Plasma level of adiponectin (R&D Systems, Minneapolis, MN, USA) was measured using commercially available enzyme-linked immunosorbent assays (ELISA). In all hormonal assays, the intra-and interassay CV for all analytes were less than 10%.
Statistics analysis
Data was analyzed using SPSS software (Version 17.0, SPSS Inc., Chicago, IL, USA). All data were presented as mean with range. The distribution of continuous variables was evaluated, and log transformations were used in the analysis as required. Differences between two groups were assessed using Student t-test, the Mann-Whitney U test, and analysis of covariance (ANCOVA) with adjustment for age and BMI.
Comparison of mean for more than three groups was performed with one-way analysis of variance (ANOVA) with post hoc tests. Correlations of AMH with other variables were expressed as Pearson correlation coefficients. To establish independent determinants of serum AMH levels, regression analysis using generalized linear model (GLM) was performed with serum AMH as the dependent variable and HOMA-IR, LH, total testosterone, E2, DHEA-S, PRL, and adiponectin levels as independent variables in each PCOS and control group. In addition, a test for differing slopes between the two groups was performed. Receiver operating characteristic (ROC) curves of the AMH, total testosterone, free testosterone, FAI, DHEAS, and SHBG levels were constructed to determine the optimal cutoff point for the diagnosis of PCOS using MedCalc software (version 11.6.0.0, Mariakerke, Belgium). P value less than 0.05 was considered statistically significant.
Results
Comparison of clinical and biochemical data between women with PCOS and control subjects
The data for women with PCOS and normal con- 
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Adiponectin (μg/mL) Among insulin resistance parameters, it is noteworthy that fasting indices, except for fasting glucose and HOMA-IR, showed no difference between PCOS and controls after adjustment for age and BMI. Therefore, 2-h post parameters might be more sensitive to diagnose insulin resistance in PCOS patients.
In biochemical parameter analysis, after classification of subjects according to obesity, the overweight/ obese PCOS group showed significantly different results from those of the other three groups (non-obese PCOS, overweight/obese controls, non-obese controls). However, serum AMH level was not higher in the overweight/obese PCOS group than in the non-obese PCOS group. There have been a few studies that have previously reported serum AMH level reflected severity of PCOS [8, 11] . Considering these earlier results, overweight/obese PCOS group could not be regarded as the more severe PCOS group although they were evaluated as distinct from the other three groups and appeared to reflect a greater influence due to obesity than observed in other groups.
To explore differences between the two groups, we performed correlation analysis and regression analysis investigating relationships between serum AMH with other variables and compared the relationships between PCOS and control groups. In the control group, age, E2, free testosterone, FAI, adiponectin, as well as total testosterone, showed significant relationships with AMH. In contrast, only total and free testosterone were significantly related with AMH in the PCOS group. These different relationships between AMH and biochemical/ clinical factors in the PCOS and control groups suggest that loss of control over AMH production by factors other than testosterone might contribute to the pathogenesis of PCOS. In normal follicle growth and development, a decrease in AMH has an inhibitory effect, allowing larger follicles to become responsive to FSH and stimulating aromatase and E2 production [22] . The lack of correlation between AMH and E2 in the PCOS group suggests that AMH no longer has an effect on aromatase and E2 production, resulting in dysregulation of folliculogenesis. Adiponectin may play an important role in the modulation of glucose and lipid metabolism in insulin-sensitive tissues, and has an increasing effect on insulin sensitivity. Hypoadiponectinemia may contribute to insulin resistance in PCOS [23] . Insulin is one of candidates for the cause of increased AMH in PCOS. Hyperinsulinemia may stimulate the development of antral follicles, increase the sensitivity of grau-
ROC curve analysis
ROC curve analysis indicated that the optimal cutoff point for AMH is 7.82 ng/mL with an area under the ROC curve (AURC) of 0.868 (95% confidence interval, 0.801-0.919), a sensitivity of 75.9% and specificity of 86.8% (Fig. 1) . The optimal cutoff point for total testosterone was 1.40 nmol/L with an AURC of 0.773 (95% confidence interval, 0.695-0.840), sensitivity of 63.2% and specificity of 83.0%. Cutoff points for free testosterone, FAI, DHEAS, and SHBG were 4.2 nmol/L (AURC 0.772, sensitivity 55.3%, specificity 88.5%), 1.8 (AURC 0.691, sensitivity 47.2%, specificity 90.6%), 3.9 μmol/L (AURC 0.652, sensitivity 78.8%, specificity 49.1%), and 59.6 nmol/L (AURC 0.691, sensitivity 47.2%, specificity 90.6%), respectively.
Discussion
We analyzed AMH and various clinical/biochemical variables, which had previously shown conflicting results in relationship analysis with AMH. In our study, women with PCOS exhibited appropriate biochemical characteristics of PCOS such as higher levels of insulin resistance parameters, lipid profiles, total testosterone, free testosterone, AMH, and lower SHBG. The white circle on the ROC curve indicates the cutoff level of 7.82 ng/mL for best sensitivity (75.9%) and specificity (86.8%). 11, 26] in women with PCOS, there was no significant relation in either PCOS or control groups in our study. Furthermore, AMH was not statistically different with respect to obesity but rather associated with PCOS status. Some studies have reported results similar to ours [9, 25, 28] , and also support the hypothesis that AMH increases due to an enhanced granulosa cell activity in vivo, which may not be body weightrelated [9] . However, the small number of subjects in this study, differences in study populations and clinical setting must all be taken into consideration. The purported relationship between insulin resistance and metabolic syndrome with AMH has been a source of controversy [26, 29] . In our study, AMH was not related to insulin resistance-or metabolic syndrome-related variables, irrespective of the PCOS status, and is in agreement with other studies [8, 11] .
In the present study, we conducted ROC curve analysis to explore the diagnostic potency of the AMH levels. Dewailly et al. [27] stated that the threshold for serum AMH level have to be determined to use the AMH level as a surrogate for HA. A cutoff level of 7.82 ng/mL (AURC 0.868, sensitivity 75.9%, specificity 86.8%) was obtained in this study. This value represents an average across the two threshold AMH concentrations previously reported, 7.3 ng/mL (sensitivity 70%, specificity 76%) [8] and 8.4 ng/mL (sensitivity 67%, specificity 92%) [25] . Differences in the cutoff values may be attributed to the different inclusion criteria. In Lin's study [8] , PCOS-risk cases with one of three PCOS components were classified into non-PCOS group, while these same PCOS-risk cases were excluded from the control group in Pigny [25] and in our study. There were a few studies that performed ROC curve analysis for the cutoff of biochemical parameters of hyperandrogenism other than AMH for the diagnosis of PCOS [30, 31] . An SHBG cutoff of 37 nmol/L (AURC 0.875, sensitivity of 87.5%, specificity of 86.8%) was the best parameter for the diagnosis of PCOS, and FAI, calculated FT, and DHEAS were also considered adequate measures for the diagnosis of PCOS in a study [30] . In Hahn's study [31] , the highest AURC was found for bioavailable testosterone (0.852) followed by FAI (0.847) and free testosterone (0.837). In the present study, AMH was the best parameter for the diagnosis of PCOS, though total testosterone with a cutoff of 1.40 nmol/L (AURC 0.773, sensitivity 63.2%, specificity 83.0%) was also adequate.
There are a few limitations in our study to be addressed. losa cells to FSH, and thus increase the number of follicles and ovarian volume [24] . Adiponectin could regulate AMH production by impacting insulin sensitivity. Data from the present study suggest that altered regulation of folliculogenesis and AMH production by aging, E2, and adiponectin might result in increased follicle numbers and AMH concentration in women with PCOS. Additional research is necessary to elucidate the role of AMH in pathogenesis of PCOS. Positive correlation of total testosterone with AMH levels has been previously reported [8, 9, 11, 13] , but some studies reported that the correlation of total testosterone with AMH was found only in the PCOS groups and not in healthy control groups [13, 25] . This result supports the hypothesis that intra-ovarian hormonal milieu is not exclusively on PCOS status [9] . Considering that AMH and total testosterone were the main determinants of ovarian volume [26] , correlation of testosterone with AMH might be true for all women, irrespective of the PCOS status. AMH is considered to be a marker of severity of PCOS [22] . These findings support the belief that intraovarian hyperandrogenism may cause follicular arrest and follicle excess followed by increased intraovarian AMH level. Nonetheless, circulating testosterone might not accurately reflect intraovarian androgen concentration and action. Based on the results of our study, total testosterone might be the most influential factor for increased AMH levels in both PCOS and control groups. In addition, elevated AMH in PCOS may be due to increased follicle numbers rather than increased production by each follicle. If elevated AMH were largely caused by an increase in production by each follicle, the amount of AMH produced by testosterone stimulation could not be predicted and thus correlation of AMH with testosterone would not be expected regardless of PCOS status. Previous research has demonstrated that an ovulatory PCOS group has lower concentrations of AMH than those who were equally hyperandrogenic but anovulatory [11] , which supports the hypothesis contrary to ours that increased AMH is due to increased production of AMH by each follicle. Dewailly et al. [27] reported that serum AMH concentrations with follicle number could be used as surrogates for classical HA markers because of the strong correlation with androgens, especially in women who have the Rotterdam PCOS phenotype without HA.
Although a few previous studies reported a significant negative relationship between BMI and AMH [8, els in the control group. This difference of associations might suggest a loss of multi-factorial control for AMH production in PCOS, and which might contribute to the pathogenesis of PCOS. Further investigation is needed to elucidate the role of AMH and the regulation mechanism of AMH production.
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First, the subjects evaluated were recruited from only one outpatient clinic of a tertiary care hospital and thus do not represent the general population. Secondly, the number of overweight/obese subjects in the control group was too small to obtain reliable results.
In conclusion, AMH levels were significantly higher in women with PCOS, regardless of age and BMI, and exhibited no relationship with obesity, insulin resistance, or metabolic syndrome-related variables. Only testosterone exhibited an influence on serum AMH levels in PCOS group, while age, E2, adiponectin as well as testosterone significantly correlated with AMH lev-
